Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCI-110 in Adults With Tourette Syndrome
NCT05126888Phase 2Not yet recruiting
- Sponsor
- Neurothera Labs Inc.
- Start
- Jun 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in Tourette syndrome (TS) comparing SCI-110 with Placebo (2 arms). Primary endpoint: Yale Global Tic Severity Scale - Revised - Total Tic Score at 12 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
dronabinol + palmitoylethanolamide
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT05126888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126888.